Sachs Associates 5th Annual North American Forum: Investing & Partnering in Biotech Presenter Profiles

http://www.sachsforum.com/boston06.html

http://www.tradeshownews.com,

Company: Advaxis Inc. Ticker Symbol & Exchange: ADXS. OB Bulletin Board Investor Relations Contact: Erik Lux; 212-825-3210 Web: www.Advaxis.com Date of Presentation: March 13, 2006 Time of Presentation: 4:30 p.m. Advaxis is developing proprietary Listeria cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes two immunological mechanisms (Innate and Classical Immunity) to develop safer and more effective Listeria-based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. Advaxis has entered a Phase I/II clinical trial for its lead Listeria vaccine candidate, Lovaxin C, which targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders. Company: Aethlon Medical, Inc. Ticker Symbol & Exchange: "AEMD" OTCBB Investor Relations Contact: Jeff Richardson; 858-459-7800, x302 Web: www.aethlonmedical.com Date of Presentation: March 13, 2006 Time of Presentation: 4:20 p.m. EST Aethlon Medical is developing the first medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com. Company: Allergy Therapeutics Plc Ticker Symbol & Exchange: AGY (London Stock Exchange, AIM) Investor Relations Contact: Mr Keith Carter; Mr. Ian Postlethwaite; +44 1903 844720 Web: www.allergytherapeutics.com Date of Presentation: 13 March Time of Presentation: 17:25 - 17:40 Allergy Therapeutics(R) plc (AGY) is a Europe-based specialty pharmaceutical company focused upon the treatment and prevention of allergy. AGY has an existing sales base of approximately GBP 23m/$40m per annum, an MHRA-approved manufacturing capability and an established sales and marketing infrastructure. The Company has the opportunity to transform the treatment of allergic disorders with its specific immunotherapy products based upon the TLR4 agonist vaccine adjuvant, MPL. It is developing ultra-shot course (4-shot) Allergy vaccines, known as Pollinex(R)Quattro. The Pollinex(R)Quattro range should improve the effectiveness of allergy immunotherapy, achieve it more safely and increase patient take-up of this method through its convenience and better compliance. Phase III studies for worldwide registration for Pollinex Quattro are scheduled to initiate in 2006. The company is also investigating MPL as an adjuvant to sub-lingual vaccines, currently in Phase IIa. Company: Apoxis SA Ticker Symbol & Exchange: Investor Relations Contact: George Bates, CFO; +41 21 620 60 93 Web: www.apoxis.com Date of Presentation: 14 March 2006 Time of Presentation: 13:55-14:10 Apoxis, a private Swiss company, exploits its world-class understanding of the mechanisms underlying apoptosis, or cell death, to develop first-in-class therapeutics for the treatment of cancer and immunological diseases. Apoxis lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. APO866 is expected to enter Phase II trials in 2006. The product is also being evaluated in a range of cancers in combination with commonly used chemo- and radiotherapies in preclinical studies. The Apoxis oncology portfolio also includes APO010, a protein therapeutic that was developed using the company's proprietary multimerization technology. It is expected to enter the clinic in 2006. Also based on Apoxis multimerization technology, APO200 is currently being developed as a treatment for a rare genetic disease. Company: Biophan Technologies, Inc. Ticker Symbol & Exchange: BIPH, OTC: BB Investor Relations Contact: Carolyn Hotchkiss; 585-214-2441 Web: www.biophan.com Date of Presentation: March 13, 2006 Time of Presentation: 11:25 a.m. Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guide wires, and implants such as stents to be safely and effectively imaged under MRI. The Company also recently announced a relationship with MYOTECH, LLC to help develop and commercialize the MYO-VAD(TM) -- a novel, MRI compatible ventricular assist device, which has significant potential for improving the treatment of heart disease. Other applications in development include novel MRI contrast agents, drug delivery technologies and power systems, which derive energy from body heat. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 50 issued U.S. patents and 106 allowed or pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, thermoelectric materials for batteries, which generate power from body heat, and optical catheter technologies. Biophan has joint development and licensing agreements with Boston Scientific Corporation and NASA's Ames Center for Nanotechnology. Biophan's goals are to make all biomedical devices capable of safely and successfully working with MRI and to deliver technologies that will improve healthcare delivery. Company: BioSante Pharmaceuticals, Inc. Ticker Symbol & Exchange: BPA Amex Investor Relations Contact: Ritu Baral; 212-477-9007, ext. 25 Web: www.biosantepharma.com Date of Presentation: March 13, 2006 Time of Presentation: 11:55 a.m. BioSante Pharmaceuticals, Inc. is a U.S.-based pharmaceutical company developing a pipeline of hormone therapy products for men and women. Symptoms in women include menopausal symptoms such as hot flashes and vaginal atrophy. Symptoms of low testosterone in women include female sexual dysfunction. The hormone therapy products are gel formulations for transdermal delivery including bio-identical testosterone for men, bio-identical estradiol for women, and bio-identical testosterone for women. BioSante also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Key products in development include: Bio-E-Gela -- a transdermal estradiol gel in development for treatment of menopausal symptoms. An NDA was submitted to the FDA for Bio-E-Gel in Q1 2006; and LibiGela -- a transdermal testosterone gel in clinical development for treatment of female sexual dysfunction. Company: Chemokine Therapeutics Ticker Symbol & Exchange: TSX: CTI & OTCBB: CHKT Investor Relations Contact: Frederica Bell; 604-827-3131 Web: www.chemokine.net Date of Presentation: Monday, March 13th Time of Presentation: 11:40-11:55 a.m. Chemokine Therapeutics is a product-focused biotechnology company developing drugs that harness the therapeutic potential of stem cells through chemokine pathways. Chemokines are a class of proteins which signal biological responses from stem cells that play a critical role in the growth, differentiation and maturation of cells necessary for fighting infection, as well as tissue repair and regeneration. Stem cells are the master primitive cells that give rise to all of the cells and organs in the body. Chemokines are one of the major mediators of stem cell activity including stem cell growth, differentiation and maturation. Chemokine Therapeutics is a leader in research in this field. The Company has five products with two lead product candidates in clinical trials: CTCE-0214, for enhancing the immune system, and CTCE-9908, to prevent the spread of cancer and its continued growth. For more information, please visit our website at www.chemokine.net. Company: ConjuGon, Inc. Ticker Symbol & Exchange: Private Investor Relations Contact: Sal Braico, Chief Operating Officer; 1-608-441-2890 Web: www.conjugon.com Date of Presentation: March 13, 2006 Time of Presentation: 5:40 p.m. ConjuGon is developing fundamentally new therapeutics to combat antibiotic resistant bacterial infections. ConjuGon's novel technology, based on research done at the University of Wisconsin-Madison, uses harmless bacteria to transfer genes into targeted, pathogenic bacteria. The genes encode for potent antibacterial proteins and compounds that quickly kill the pathogenic bacteria. Through a collaboration with the Loyola University Medical Center outside of Chicago, ConjuGon's technology effectively cured infections caused by antibiotic-resistant bacteria, including bacteria resistant to all antibiotics, in a murine wound infection model. ConjuGon is currently raising a Series A round of financing from venture capitalists. Company: DeveloGenAG Ticker Symbol & Exchange: Investor Relations Contact: Mrs. Kathrin Shem-Tov; +49 551 50558525 Web: www.develogen.com Date of Presentation: 14. March 2006 Time of Presentation: 13.40-13.55 DeveloGen is a biopharmaceutical company engaged in the discovery and development of novel therapeutic drugs for the treatment of metabolic disorders, such as type 1 and type 2 diabetes, as well as diabetic complications. The objective of DeveloGen is to address unmet medical needs by leveraging its expertise and in-depth understanding of the disease-related biology and medical implications of autoimmune and diabetic complications. The Company has a broad and innovative pipeline from lead discovery to phase III clinical development. DeveloGen is headquartered in Goettingen, Germany, with additional sites in Rehovot, Israel, and Erkrath, Germany. Company: Diamyd Medical AB (publ) Ticker Symbol & Exchange: DIAM B OMXS (Stockholm Stock Exchanfe) Investor Relations Contact: Anders Essen-Moller; +46 70 551 06 79 Web: www.diamyd.com Date of Presentation: March 13 Time of Presentation: 11:40 - 11:55 Founded in 1996, Diamyd Medical (OMXS: DIAM B) is an emerging and global biotechnology company based in Stockholm, Sweden, and Pittsburgh, Pa., USA. The Company is focused on developing therapeutics for diabetes, pain and cancer as well as on protein delivery using a proprietary gene delivery technology platform. Diamyd Medical conducts therapeutic development based on its GAD (Glutamic Acid Decarboxylase) molecule. GAD is an enzyme that converts the excitatory neurotransmitter glutamate to the inhibitory transmitter GABA. In this context GAD may have an important role in CNS-related disease. GAD is also a target pancreatic beta cell autoantigen in autoimmune diabetes, such autoimmunity leading to development of insulin-dependence. Diamyd Medical's furthest developed project is Diamyd, which is currently employed in two ongoing clinical Phase II trials of both Type 2 and Type 1 diabetes. Other mainstream developments include using a proprietary Nerve-Target Delivery System to deliver GAD to treat diabetes pain and neuropathy. Company: Ensemble Discovery Ticker Symbol & Exchange: Investor Relations Contact: Richard Begley, Ph.D., President and CEO; 617-492-6977, x233 Web: www.ensemblediscovery.com Date of Presentation: Monday March 13 Time of Presentation: 17.10-17.25 Ensemble Discovery Corporation is developing a novel approach to chemical discovery based on a highly integrated set of processes that combine chemistry, biology and nanotechnology. Central to our approach is DNA Programmed Chemistry (DPC), an innovative method for chemical synthesis based on the groundbreaking work of Professor David Liu of Harvard University. DPC employs short complementary DNA strands with chemical moieties attached at each end to drive chemical reactions, creating new bonds and novel compounds. Libraries containing complex, diverse, pure and soluble drug-like small molecules can be generated in a single pot. A nanoscale affinity-based selection system is then used to identify binders with a wide dynamic range and to efficiently generate comprehensive, data-driven SAR. Ensemble is applying the technology to identify unprecedented chemical bond formations as well as to discover human therapeutics and detection products, including research tools, clinical diagnostics, and other specialty chemicals. The company has a broad intellectual property portfolio and has raised capital from a premier group of investors. Located in Cambridge, Mass., Ensemble has assembled a world-class team of scientists and entrepreneurs and aims to generate new products that address significant unmet needs. Company: Evolutec Group plc Ticker Symbol & Exchange: EVC Exchange - London AIM Investor Relations Contact: Nicholas Badman; +44 118 922 4488 Web: www.evolutec.co.uk Date of Presentation: Monday, 13th March Time of Presentation: 11.55-12.10 Evolutec is a biopharmaceutical company focused on drug development for allergy, inflammation and auto-immune diseases. Evolutec is based in Reading, UK. Evolutec's lead drug candidate, rEV131 appears to work in both acute and chronic respiratory indications including asthma and COPD (bronchitis). Early stage results also indicate potential efficacy in ophthalmic indications including conjunctivitis and post-cataract surgery. This unusual breadth of activity may result from rEV131's novel mechanism of action. Evolutec recently announced a positive result for rEV131 in a 112 patient Phase IIa study in allergic rhinitis (severe hay fever). rEV131 met the primary efficacy endpoint (p less than 0.05). In addition, rEV131 showed efficacy against mucus and congestion, the most difficult to treat symptoms of rhinitis, and a rapid onset of action (less than 45 minutes). Evolutec intends to carryout a Phase IIb 300-400 patient rhinitis trial using a multi-dose device. In addition, rEV131 will undergo proof of concept trials in post-cataract surgery and dry eye, such that by the end of 2006 Evolutec will have Phase II data in three disease areas. Evolutec has two other preclinical molecules, rEV576 and rEV598, which are currently being evaluated. rEV576 is a complement inhibitor and is being assessed for its potential in myasthenia gravis and certain acute coronary conditions including acute myocardial infarction ("AMI"). Evolutec recently announced positive preclinical results for rEV576 in myasthenia gravis a severe autoimmune disease, and AMI. rEV598 binds serotonin and is being examined for CINV (chemotherapy induced nausea and vomiting). Evolutec's management intend to create a range of commercial options across its family of proteins including licensing out the sales rights in primary care markets and retaining the rights in specialist markets. For example, Evolutec will seek a partner for rEV131 in respiratory indications, including allergic rhinitis and asthma, but will retain the rights to rEV131 in ophthalmic indications including dry eye and post-cataract surgery. Company: IBEX Technologies Inc. Ticker Symbol & Exchange: TO.IBT Investor Relations Contact: Paul Baehr, President and Chief Executive Officer Investor Relations Contact Phone: Donna Lavoie or Bryan Murphy; 781-596-0200, x 103 or X 105 Web: www.ibex.ca Date of Presentation: March 13 Time of Presentation: 12:10 IBEX Technologies Inc. (TSX: IBT) is a biopharmaceutical company utilizing its expertise in disease related biomolecules to develop therapeutics and diagnostics for the management of cancer and arthritis. The Company's cancer program is based on a novel family of genes known as kallikreins. IBEX is investigating the role of kallikreins in metastatic disease, as well as developing kallikrein-based diagnostics for the screening and monitoring of cancer. The Company's arthritis program is based on a series of biomarkers of cartilage degradation and synthesis. IBEX arthritis assays are used by leading pharmaceutical companies for research purposes. The Company also markets a number of products, including its proprietary enzymes (heparinases and chondroitinases) and a series of arthritis and kallikrein assays. IBEX(TM) Heparinase I is used in many leading point-of-care hemostasis monitoring devices. IBEX's central business strategy is to develop its core oncology products in-house through demonstration of clinical efficacy, prior to establishing commercial partnerships. Company: immatics Investor Relations Contact: Joerg Scheidle (Managing Director, CFO); +49 (0)7071 565 125 14 Web: www.immatics.com Date of Presentation: Monday, 13 March 2006 Time of Presentation: 5:10 p.m. immatics is a biopharmaceutical company dedicated to the development of innovative cancer vaccines. immatics' proprietary basis of tumor-associated peptides (TUMAPs) provides a huge opportunity for development of novel anti-cancer vaccines. With the discovery engine XPRESIDENT(TM), immatics owns a unique technology allowing the identification of thousands of TUMAPs directly from primary tumor tissue. Having shown promising clinical results for first TUMAPs in pilot trials, immatics has entered clinical Phase 1 trials in November 2005 for its first multi-TUMAP product candidate IMA901 treating renal cell carcinoma (RCC) and recently completed enrollment well ahead of plan. Final study results for this product candidate are expected for 3Q 2006. Several product candidates for even larger oncology indications, including a product candidate for the treatment of colorectal cancer, are currently in pre-clinical development and will be ready for transition to phase 1 clinical testing in the next 12 to 18 months. immatics was founded in 2000 as a spin-off from the Institute of Immunology at the University of Tuebingen (Hans-Georg Rammensee). Company: Ingenium Pharmaceuticals AG Ticker Symbol & Exchange: Investor Relations Contact: Michael Grau; 0049-89-8565-2300 (main) Web: www.ingenium-ag.com Date of Presentation: Monday, 13th March Time of Presentation: 17.55 - 18.15 Ingenium Pharmaceuticals is leveraging its expertise in drug target discovery and genetics-based therapeutic research toward the development of novel treatments for pain and inflammatory disease. To date, Ingenium has successfully used its unique forward and reverse genetics approaches for its internal drug development programs and for its partners. Ingenium's largest partnership is a multi-year drug discovery and development collaboration with Elan in the area of neuropathic pain. In addition, Ingenium has signed numerous agreements across the biopharmaceutical industry and academia to provide genetic expertise and animal models. As the lead program in its portfolio, Ingenium has identified a novel mechanism for the treatment of neuropathic and inflammatory pain. This mechanism is based on the suppression of pro-inflammatory cytokines through a novel kinase-class target. Using advanced lead compounds, Ingenium scientists have established proof of concept in various animal models for both neuropathic and inflammatory pain. To date, the compound series has demonstrated good, pharmacokinetic properties, and Ingenium will continue its drug discovery efforts toward defining a preclinical developmental candidate by the end of 2006. Company: Liponex Inc Ticker Symbol & Exchange: LPX:TSX Investor Relations Contact: Nick Hurst; 416-815-0700, ext. 226 Web: www.liponex.ca Date of Presentation: Monday, March 13, 2006 Time of Presentation: 12:25 p.m. E.S.T. Liponex Inc. is a publicly traded biopharmaceutical research company that is developing a proprietary technology to treat heart disease, cancer, and infectious disease, the world's three biggest health care markets. Liponex has a lead product for the treatment of heart disease, called CRD5, which raises High Density Lipoprotein (HDL), often called "good cholesterol." CRD5 has successfully completed three Phase I human trials that demonstrated the product was safe and well tolerated with no significant adverse events. These studies confirmed preclinical animal data findings and demonstrated that CRD5 can cause a significant increase in HDL levels (~20%) while also lowering triglyceride levels (~40%). Liponex intends to conduct its first Phase I/II clinical trial with CRD5 in 2006. Data from this trial will be used to determine an optimal dose for a second Phase II trial. The Company also intends to selectively advance preclinical development of other compounds in its pipeline. Company: Manhattan Pharmaceuticals, Inc. Ticker Symbol & Exchange: AMEX: MHA Investor Relations Contact: Michelle Carroll - Corporate Communications; 212-582-3950; mcarroll@manhattanpharma.com Web: www.manhattanpharma.com Date of Presentation: 13-March-06 Time of Presentation: 12:55 - 1:10 p.m. Manhattan Pharmaceuticals, Inc. (AMEX: MHA), a development stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures. Company: Meditech Research Limited Ticker Symbol & Exchange: MTR (ASX) Investor Relations Contact: Mary Bennett; +61 3 9296 2043 Web: www.mrl.com.au Date of Presentation: 13th March 2006 Time of Presentation: 16.40 - 16.55 Meditech is an Australian biotechnology company focused on developing and commercialising drugs that improve the health and quality of life of patients with cancer and other chronic diseases. The company has internationally recognised expertise in carbohydrate-based therapies, particularly products based upon the glycosaminoglycan, hyaluronic acid. Building on this expertise, Meditech has created its patented HyACT(TM) (Hyaluronic Acid Chemotransport Technology) platform, which it is applying to the development of improved formulations of cancer drugs. The lead product from the HyACT(TM) platform is HyCAMP(TM), which is in phase II clinical trials. In addition to HyCAMP(TM), Meditech has taken the anti-cancer products HyDOX(TM) (doxorubicin and hyaluronic acid) and HyFIVE(TM) (5-fluorouracil and hyaluronic acid) into clinical testing. HyACT(TM) (Hyaluronic Acid Chemotransport Technology) is a proprietary platform technology, which can potentially be applied to a wide range of cytotoxic cancer drugs, both proprietary and generic. The formulations of HA with cytotoxic drugs results in increased efficacy and a reduction in treatment toxicities through novel delivery mechanisms. Company: MorphoSys AG Ticker Symbol & Exchange: Frankfurt Stock Exchange (FSE): MOR Investor Relations Contact: Dr. Claudia Gutjahr-Loser; gutjahr@morphosys.com; +49 89 89927 122 Web: www.morphosys.com Date of Presentation: March 13, 2006 Time of Presentation: 12:.10-12.25 MorphoSys is one of the world's leading biotechnology companies focusing on fully human antibodies. With its proprietary technologies, MorphoSys is developing not only the next generation of therapeutic antibodies, but also antibodies for research and diagnostics purposes. HuCAL(R) (Human Combinatorial Antibody Library) is a very powerful technology for the rapid and automated production of specific antibodies. The most distinctive feature of the library is the capability to optimize fully human antibodies to predefined specifications, allowing MorphoSys to "Engineer the Medicines of Tomorrow." MorphoSys' goal is to establish HuCAL(R) as the technology of choice for antibody generation in all market sectors. Company: Santhera Pharmaceuticals AG Investor Relations Contact: Barbara Heller; +41 61 906 89 54 Web: www.santhera.com Date of Presentation: 14 March 2006 Time of Presentation: 2:10 p.m. Santhera Pharmaceuticals AG is a Swiss biopharmaceutical company focused on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of neuromuscular diseases. The company's lead product, SNT-MC17 (idebenone), is in a European Phase III for the treatment of Friedreich's Ataxia, a rare but devastating disease, which is ultimately fatal. Santhera has orphan drug designations for this indication in both the U.S. and EU. The Company intends to market the product in the U.S. and has exclusively licensed the rights to market the product for FRDA in Europe to Takeda. Santhera is also conducting a Phase II trial in Duchenne Muscular Dystrophy with SNT-MC17 (idebenone). Santhera has developed a pipeline of preclinical drug candidates, which it will progress in neuromuscular diseases and outlicense in areas outside its core therapeutic focus. Santhera's program on novel DPP IV inhibitors for the treatment of metabolic diseases, including Type II diabetes, is licensed to Biovitrum (Sweden). Santhera was formed in 2004 through the merger of MyoContract AG and Graffinity Pharmaceuticals AG. The Company has operations in Basel, Switzerland, and Heidelberg, Germany. Santhera has attracted investment from leading global industry investors including NGN Capital, Oxford Bioscience Partners, Merlin Biosciences Limited, 3i Group plc, Carnegie Asset Management, Varuma AG, The Novartis Venture Fund, GIMV, Heidelberg Innovation, Altana Innovationsfonds, Clariden Bank, The Dow Chemical Company, TechnoStart, tbg, the Swiss Foundation for Research on Muscle Diseases, and private investors. Company: Sapphire Therapeutics, Inc. Ticker Symbol & Exchange: NA Investor Relations Contact: Gary C. Cupit, PharmD, President and CEO; 908-203-6545 Web: www.sapphirethera.com Date of Presentation: Monday, March 13, 2006 Time of Presentation: 5:25 p.m. Sapphire Therapeutics is a private biopharmaceutical company committed to developing and commercializing promising compounds ready for clinical or preclinical testing. Sapphire's drug development team collectively has brought over 80 approved drugs to market and includes senior management from Merck, Novartis, Aventis, Akros and Alexion, whose responsibilities ranged from research, to safety assessment, to process research, to development and commercialization. The Company utilizes its breadth of experience in drug development and contacts in the pharmaceutical industry to select early stage compounds for commercialization. Sapphire's first portfolio of novel compounds, a collection of orally deliverable, small molecular ghrelin agonists, have entered Phase II human clinical studies for cancer anorexia and cachexia (CAC). This affects an estimated 70% of patients diagnosed with neoplastic disease. Current treatments for CAC are utilized in a relatively small percentage of patients and are limited in their therapeutic effect. However, studies with ghrelin and ghrelin mimetics have been shown to stimulate appetite and reverse nitrogen loss. Management believes this will translate into a market opportunity greater than $600 million. A second compound with an oncology therapeutic indication is in Phase I. Company: Swiss Medica Ticker Symbol & Exchange: SWME. OB, NASD OTC Investor Relations Contact: Dave Jones; djones@swissmedica.com; 705-495-5500 Web: www.swissmedica.com Date of Presentation: March 13, 2006 Time of Presentation: 11:40-11:55 a.m. Swiss Medica commercializes patented, clinically tested, all-natural, OTC products that relieve chronic ailments: -- O24 Pain Neutralizer is a topical analgesic and anti-inflammatory, which has been praised for its safe and fast-acting pain reduction benefits by physicians. -- O24 Fibromyalgia is the first clinically tested OTC product for Fibromyalgia available in North American pharmacies and was awarded the first Seal of Approval by the National Fibromyalgia Association. -- PMS Escape is clinically proven to reduce the mood and appetite symptoms that women experience during the premenstrual period. Swiss Medica's products are available in over 21,000 retailers including Walgreens, CVS and Rite-Aid. Company: TOPIGEN Pharmaceuticals Inc. Investor Relations Contact: John Mohr; 973-809-5582 Web: www.topigen.com Date of Presentation: March 14, 2006 Time of Presentation: 1:55 p.m. TOPIGEN is a privately-held biopharmaceutical company focused on respiratory care. The company is developing several new classes of drugs and is actively progressing two drug candidates in Phase II trials for COPD and asthma. These drugs are uniquely focused on inhibiting multiple inflammation targets underlying the chronic pulmonary diseases. TOPIGEN also has a number of discovery research programs focused on the identification of novel compounds for the treatment of COPD and allergic rhinitis. By applying its knowledge and expertise in respiratory care, along with its proprietary mRNA-based chemistry, TOPIGEN is seeking to make a positive difference for patients. TOPIGEN is uniquely focused on developing products for the treatment of pulmonary diseases using both traditional small molecule chemistry and mRNA-based chemistry to target multiple inflammation pathways and mediators. The drugs are delivered directly to the site of action using topical inhalation technology. We are seeking licensing and co-development arrangements on our lead drug candidates. In addition, we are building our pipeline and actively seek clinical-stage respiratory and pulmonary drug candidates that complement our development expertise and meet our commercial criteria. Ideal in-licensing candidates are programs with sufficient pulmonary activity and toxicological data. For more information, visit www.topigen.com. Company: VioQuest Pharmaceuticals Ticker Symbol & Exchange: OTCBB: VQPH Investor Relations Contact: Daniel E. Greenleaf and Brian Lenz; 212-825-3210 Web: www.vioquestpharm.com Date of Presentation: Monday, March 13, 2006 Time of Presentation: 12:25 - 12:40 p.m. ET VioQuest's strategy is to acquire, develop, and commercialize targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. The Company is developing two novel targeted anti-cancer agents, VQD-001 and VQD-002, for the treatment of melanoma, myeloma, lymphoma; and breast, leukemia, ovarian, pancreatic, colorectal cancers, respectively. VioQuest's subsidiary Chiral Quest, a pioneer in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug. Company: VIRxSYS Investor Relations Contact: Dr. Riku Rautsola; 301-987-0480, ext. 223 Web: www.virxsys.com Date of Presentation: March 13, 2006 Time of Presentation: 16:20 The Company founded in Gaithersburg, Md., in 1998, is a private biotechnology company whose mission is to develop gene-based therapies using its proprietary lentiviral vector-based delivery system. The first application of the Company's novel gene delivery technology has been for treatment of HIV, the virus that causes AIDS. After a successful first-in-class Phase I clinical trial that demonstrated the safety profile of the Company's product VRX496, this new ex-vivo anti-HIV treatment using a lentivector currently is being evaluated in the first ever phase II clinical trial approved by the FDA involving a lentiviral vector. The Company's lentiviral vector platform is an ideal delivery system for the effective treatment of disease. The Company's vector technology is also being investigated for applications in anti-cancer therapies and the treatment of other various life threatening diseases.